RHEUM || FDA & CDC

Secukinumab earns FDA approval for plaque psoriasis

Posted on: 21/01/2015 - 21:38

The U.S. Food and Drug Administration has approved secukinumab for the treatment of moderate to severe plaque psoriasis in adults. The injectable interleukin-17A inhibitor is indicated for...

Field of Interest: Dermatology

Type: News Item

Veterans more likely to have arthritis at any age

Posted on: 12/11/2014 - 16:35

Both male and female veterans were more likely to have arthritis than were nonveterans, according to a study from the Centers for Disease Control and Prevention. For male veterans, the...

Field of Interest: Rheumatology

Type: News Item

FDA panel unanimously supports secukinumab approval for psoriasis

Posted on: 20/10/2014 - 23:15

SILVER SPRING, MD. – The human monoclonal antibody secukinumab is expected to be the first biologic that targets interleukin-17A to be approved by the agency for treating psoriasis, with a Food and...

Field of Interest: Dermatology

Type: News Item

Secukinumab earns FDA approval for plaque psoriasis

Veterans more likely to have arthritis at any age

FDA panel unanimously supports secukinumab approval for psoriasis

Newsletters

Latest Newsletters

You are here

RHEUM || FDA & CDC

Secukinumab earns FDA approval for plaque psoriasis

Veterans more likely to have arthritis at any age

FDA panel unanimously supports secukinumab approval for psoriasis

Newsletters

Latest Newsletters